Matteo Dugo: Neoadjuvant atezolizumab plus chemotherapy in TNBC

Matteo Dugo shared a post on LinkedIn, about recent paper published in Clinical Cancer Research:

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Authors: Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Antón-Torres, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini.

”I am proud to share our latest publication on AACR Journals Clinical Cancer Research: ‘The immune-related 27-gene signature DetermaIO predicts response to neoadjuvant atezolizumab plus chemotherapy in triple-negative breast cancer’ led by Dr. Giampaolo Bianchini.

You can find the full open access paper here.

We thank AIRC – Foundation for Cancer Research NGO, Fondazione Michelangelo and The Breast Cancer Research Foundation for their support.”

Source: Matteo Dugo/LinkedIn

Matteo Dugo is a Bioinformatician working in breast cancer research at IRCCS Ospedale San Raffaele, Milan, Italy. He earned his PhD from The Open University.